Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy

BMC Gastroenterology

Research Article

Li Yao¹  Lei Xia²  Liangxi Pan³  Sheng Li³  Liangjun Zhu³ 

[1] Department of Hematology, First Hospital Affiliated to Suzhou University, 215000, Suzhou, China;Department of Pathology, Jiangsu Tumor Hospital, 210000, Nanjing, China;Oncology, Jiangsu Tumor Hospital, NO.42 bai zi ting, 210000, Nanjing, China;

关键词: Colorectal cancer;    ERCC1;    TS;    Real-time PCR;    Adjuvant chemotherapy;   

DOI  :  10.1186/1471-230X-14-154

 received in 2014-01-17, accepted in 2014-08-21,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundAim was to explore the association of ERCC1 and TS mRNA levels with the disease free survival (DFS) in Chinese colorectal cancer (CRC) patients receiving oxaliplatin and 5-FU based adjuvant chemotherapy.MethodsTotal 112 Chinese stage II-III CRC patients were respectively treated by four different chemotherapy regimens after curative operation. The TS and ERCC1 mRNA levels in primary tumor were measured by real-time RT-PCR. Kaplan–Meier curves and log-rank tests were used for DFS analysis. The Cox proportional hazards model was used for prognostic analysis.ResultsIn univariate analysis, the hazard ratio (HR) for the mRNA expression levels of TS and ERCC1 (logTS: HR = 0.820, 95% CI = 0.600 - 1.117, P = 0.210; logERCC1: HR = 1.054, 95% CI = 0.852 - 1.304, P = 0.638) indicated no significant association of DFS with the TS and ERCC1 mRNA levels. In multivariate analyses, tumor stage (IIIc: reference, P = 0.083; IIb: HR = 0.240, 95% CI = 0.080 - 0.724, P = 0.011; IIc: HR < 0.0001, P = 0.977; IIIa: HR = 0.179, 95% CI = 0.012 - 2.593, P = 0.207) was confirmed to be the independent prognostic factor for DFS. Moreover, the Kaplan-Meier DFS curves showed that TS and ERCC1 mRNA levels were not significantly associated with the DFS (TS: P = 0.264; ERCC1: P = 0.484).ConclusionThe mRNA expression of ERCC1 and TS were not applicable to predict the DFS of Chinese stage II-III CRC patients receiving 5-FU and oxaliplatin based adjuvant chemotherapy.

【 授权许可】

CC BY   
© Li et al.; licensee BioMed Central Ltd. 2014